Marizyme Statistics
Total Valuation
Marizyme has a market cap or net worth of $4.43 million. The enterprise value is $25.55 million.
| Market Cap | 4.43M |
| Enterprise Value | 25.55M |
Important Dates
| Earnings Date | n/a |
| Ex-Dividend Date | n/a |
Share Statistics
Marizyme has 46.67 million shares outstanding. The number of shares has increased by 12.21% in one year.
| Shares Outstanding | 46.67M |
| Shares Change (YoY) | +12.21% |
| Shares Change (QoQ) | +6.08% |
| Owned by Insiders (%) | 32.31% |
| Owned by Institutions (%) | 0.01% |
| Float | 13.85M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 7.50 |
| Forward PS | n/a |
| PB Ratio | n/a |
| P/FCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 43.25 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 0.03
| Current Ratio | 0.03 |
| Quick Ratio | 0.01 |
| Debt / Equity | n/a |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -78.36 |
Financial Efficiency
| Return on Equity (ROE) | n/a |
| Return on Assets (ROA) | -278.24% |
| Return on Capital (ROIC) | n/a |
| Revenue Per Employee | $45,455 |
| Profits Per Employee | -$7.90M |
| Employee Count | 13 |
| Asset Turnover | 0.02 |
| Inventory Turnover | 0.96 |
Taxes
In the past 12 months, Marizyme has paid $38.77 million in taxes.
| Income Tax | 38.77M |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +5.44% in the last 52 weeks. The beta is 0.17, so Marizyme's price volatility has been lower than the market average.
| Beta (1Y) | 0.17 |
| 52-Week Price Change | +5.44% |
| 50-Day Moving Average | 0.09 |
| 200-Day Moving Average | 0.13 |
| Relative Strength Index (RSI) | 57.75 |
| Average Volume (30 Days) | 3,537 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Marizyme had revenue of $590,912 and -$102.73 million in losses. Loss per share was -$2.41.
| Revenue | 590,912 |
| Gross Profit | 423,246 |
| Operating Income | -13.94M |
| Pretax Income | -79.15M |
| Net Income | -102.73M |
| EBITDA | -37.73M |
| EBIT | -38.57M |
| Loss Per Share | -$2.41 |
Balance Sheet
The company has $474,944 in cash and $21.60 million in debt, giving a net cash position of -$21.12 million or -$0.45 per share.
| Cash & Cash Equivalents | 474,944 |
| Total Debt | 21.60M |
| Net Cash | -21.12M |
| Net Cash Per Share | -$0.45 |
| Equity / Book Value | -21.95M |
| Book Value Per Share | -0.47 |
| Working Capital | -47.35M |
Cash Flow
| Operating Cash Flow | -5.06M |
| Capital Expenditures | n/a |
| Free Cash Flow | -5.06M |
| FCF Per Share | -$0.11 |
Margins
Gross margin is 71.63%, with operating and profit margins of -2,358.68% and -17,384.15%.
| Gross Margin | 71.63% |
| Operating Margin | -2,358.68% |
| Pretax Margin | -13,393.81% |
| Profit Margin | -17,384.15% |
| EBITDA Margin | -6,385.19% |
| EBIT Margin | -6,527.56% |
| FCF Margin | -855.80% |
Dividends & Yields
Marizyme does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -12.21% |
| Shareholder Yield | -12.21% |
| Earnings Yield | -2,317.10% |
| FCF Yield | -114.07% |
Analyst Forecast
| Price Target | n/a |
| Price Target Difference | n/a |
| Analyst Consensus | n/a |
| Analyst Count | n/a |
| Revenue Growth Forecast (5Y) | n/a |
| EPS Growth Forecast (5Y) | n/a |
Stock Splits
The last stock split was on July 27, 2018. It was a reverse split with a ratio of 1:29.
| Last Split Date | Jul 27, 2018 |
| Split Type | Reverse |
| Split Ratio | 1:29 |
Scores
Marizyme has an Altman Z-Score of -10.29 and a Piotroski F-Score of 4. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -10.29 |
| Piotroski F-Score | 4 |